Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...

Investing.com — Foghorn Therapeutics Inc . (NASDAQ: FHTX )，一家市值为2.3135亿美元的制药公司，宣布修改其与TD Securities (USA) LLC的普通股销售协议，有效降低了其场内交易 (ATM)发行的潜在股票销售规模。今天进行的这项修订将可用股份从2亿美元缩减至1亿美元。

Foghorn Therapeutics Inc. announced continued enrollment in its Phase 1 trial for FHD-909, a first-in-class oral selective SMARCA2 inhibitor targeting SMARCA4 mutated cancers, particularly non ...

March 06, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting ...

Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Free Report) have earned a consensus rating of “Buy” from the six ...

A malfunctioning foghorn has been blaring every 30 seconds off the coast of a Narragansett, Rhode Island, beach for the last few weeks. Narragansett residents spoke to NBC 10 about the relentless ...